-$0.84 Earnings Per Share Expected for Menlo Therapeutics Inc (MNLO) This Quarter

Brokerages expect Menlo Therapeutics Inc (NASDAQ:MNLO) to announce ($0.84) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Menlo Therapeutics’ earnings, with estimates ranging from ($0.91) to ($0.76). The firm is scheduled to announce its next earnings results on Wednesday, August 8th.

According to Zacks, analysts expect that Menlo Therapeutics will report full year earnings of ($3.20) per share for the current year, with EPS estimates ranging from ($3.34) to ($3.05). For the next fiscal year, analysts anticipate that the business will post earnings of ($3.35) per share, with EPS estimates ranging from ($3.56) to ($3.14). Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Menlo Therapeutics.

Menlo Therapeutics (NASDAQ:MNLO) last posted its quarterly earnings results on Wednesday, May 9th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.06). The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.56 million.



Several equities research analysts have weighed in on MNLO shares. Guggenheim started coverage on Menlo Therapeutics in a research report on Monday, February 19th. They issued a “buy” rating and a $52.00 target price on the stock. Jefferies Group started coverage on Menlo Therapeutics in a research report on Tuesday, February 20th. They issued a “buy” rating and a $41.00 target price on the stock. Piper Jaffray Companies started coverage on Menlo Therapeutics in a research report on Tuesday, February 20th. They issued an “overweight” rating and a $48.00 target price on the stock. JMP Securities started coverage on Menlo Therapeutics in a research report on Tuesday, February 20th. They issued an “outperform” rating and a $44.00 target price on the stock. Finally, ValuEngine raised Menlo Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $30.80.

Hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System acquired a new stake in Menlo Therapeutics in the first quarter worth $368,000. Citadel Advisors LLC bought a new position in shares of Menlo Therapeutics in the first quarter worth $535,000. Eventide Asset Management LLC bought a new position in shares of Menlo Therapeutics in the first quarter worth $940,000. Schwab Charles Investment Management Inc. bought a new position in shares of Menlo Therapeutics in the first quarter worth $1,084,000. Finally, Landscape Capital Management L.L.C. bought a new position in shares of Menlo Therapeutics in the first quarter worth $1,119,000. 67.11% of the stock is currently owned by hedge funds and other institutional investors.

Menlo Therapeutics traded down $0.20, hitting $7.80, during trading hours on Friday, according to MarketBeat Ratings. The company had a trading volume of 3,355 shares, compared to its average volume of 129,887. Menlo Therapeutics has a fifty-two week low of $6.99 and a fifty-two week high of $39.86. The firm has a market capitalization of $185.89 million and a PE ratio of -1.41.

Menlo Therapeutics Company Profile

Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis.

Get a free copy of the Zacks research report on Menlo Therapeutics (MNLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply